EJ HCPCS Level II modifier: Subsequent claims for a defined course of therapy, e.g., epo, sodium hyaluronate, infliximab
EJ is a HCPCS Level II modifier: “Subsequent claims for a defined course of therapy, e.g., epo, sodium hyaluronate, infliximab.” It adds this detail to the code it is reported with.
Official description
EJSubsequent claims for a defined course of therapy, e.g., epo, sodium hyaluronate, infliximab
Short description: Subsequent claim
HCPCS · United States
Medicare details
The indicators CMS publishes with EJ in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Added
- Jan 1, 1991
Where EJ sits
- 1GroupHCPCS modifiers
- 2Modifier EJSubsequent claims for a defined course of therapy, e.g., epo, sodium hyaluronate, infliximab
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code EJ mean?
EJ is the HCPCS code for “Subsequent claims for a defined course of therapy, e.g., epo, sodium hyaluronate, infliximab” in CMS’s HCPCS Level II October 2026 release.
Where is EJ in the HCPCS Level II list?
EJ is listed under Modifiers.
Does Medicare cover EJ?
CMS lists EJ’s Medicare coverage as “Special coverage instructions apply”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside EJ
All modifiersE4Lower right, eyelidEAErythropoietic stimulating agent (esa) administered to treat anemia due to anti-cancer chemotherapyEBErythropoietic stimulating agent (esa) administered to treat anemia due to anti-cancer radiotherapyECErythropoietic stimulating agent (esa) administered to treat anemia not due to anti-cancer radiotherapy or anti-cancer chemotherapyEDHematocrit level has exceeded 39% (or hemoglobin level has exceeded 13.0 g/dl) for 3 or more consecutive billing cycles immediately prior to and including the current cycleEEHematocrit level has not exceeded 39% (or hemoglobin level has not exceeded 13.0 g/dl) for 3 or more consecutive billing cycles immediately prior to and including the current cycleEMEmergency reserve supply (for esrd benefit only)EPService provided as part of medicaid early periodic screening diagnosis and treatment (epsdt) programERItems and services furnished by a provider-based, off-campus emergency departmentETEmergency servicesEXExpatriate beneficiaryEYNo physician or other licensed health care provider order for this item or service